Linde (LIN) Q3 2026 Earnings Call Transcript

Linde reported third-quarter sales of $9.4 billion, up 9%, and adjusted EPS of $4.59, up 9% year over year; adjusted operating profit rose 8% to $2.8 billion. The company recorded a $425 million restructuring charge, while adjusted operating margin was flat year over year excluding cost pass-through, and management cited Lincare as a headwind. Linde forecast fourth-quarter adjusted EPS of $4.40–$4.50, up 5%–7%, and maintained full-year guidance of $17.82–$17.92; it also reported more than $9 billion of year-to-date capital deployment, with roughly half returned to shareholders.

Analysis

The quality of growth matters more than the headline EPS beat: underlying volume remains modest, while price includes recovery of cost inflation that can lift revenue without improving unit economics. Flat margins excluding pass-through therefore make sustained productivity and mix improvement the key test—not further price-led sales growth. A reversal in energy or distribution costs could also unwind some of the recent pricing benefit after the contractual recovery lag.

The clearest structural upside is electronics: project start-ups can add recurring sale-of-gas volumes and density, but require substantial execution and customer ramp-up; backlog is not near-term earnings. Conversely, Europe’s stagnant industrial base and China’s export-heavy growth leave the cycle exposed to trade friction and weak domestic demand. The Woodside ramp is a separate execution watch: delayed customer demand could defer incremental supply economics, while existing network molecules have an opportunity cost. ExxonMobil’s role in the project’s carbon-capture component is not, by itself, a material read-through to ExxonMobil Holdings Corporation.

Near term, cautious guidance and a sequential EPS decline may cap enthusiasm despite resilient core operations. Over 1–3 months, watch the February 2027 outlook, price-cost conversion, and evidence that restructuring translates into savings. Over 6–18 months, electronics start-ups and cost actions can support growth; Lincare remains an uncertain drag, with a sale not assured. Contrarian point: market focus on record EPS may underweight flat underlying margins, but treating Lincare as an imminent disposal would overstate an unconfirmed option. Without valuation and post-call price data, there is no evidence-based entry level.

Key Decisions for Investors

• Do not chase LIN solely on the reported EPS growth; require evidence that margins improve excluding pass-through before adding cyclical earnings exposure.
• Set a catalyst watch for the February 2027 outlook: test whether Linde quantifies restructuring savings and whether underlying pricing offsets inflation without relying on temporary cost recovery.
• Track electronics project commissioning and customer ramp timing, alongside the Woodside start-up schedule; backlog conversion delays would weaken the medium-term growth case.
• Keep Lincare divestiture as optionality, not a base-case catalyst. Reassess if management reports sustained operating improvement or confirms a credible strategic process.